Saturday - January 11, 2025
Litigation: SEC Charges Ex-CEO of Biotherapeutics Company With Misleading Investors About Status of FDA Reviews
December 04, 2024
WASHINGTON, Dec. 4 -- The Securities and Exchange Commission issued the following litigation release (No. 4:24-cv-04729; S.D. Tex., filed Dec. 3, 2024) involving Maurizio Chiriva-Internati:

* * *

The Securities and Exchange Commission today filed settled charges against Maurizio Chiriva-Internati, the former CEO of Houston-based biotherapeutics company, Kiromic BioPharma, Inc., for failing to disclose material information about Kiromic's two cancer fighting drug ca . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products